Skip to main content
Premium Trial:

Request an Annual Quote

Natera, Feinstein Institute Partner on Noninvasive Cancer Diagnostics Research

NEW YORK (GenomeWeb) – Natera and the Feinstein Institute for Medical Research will partner to conduct research on cell-free circulating tumor DNA in order to detect, diagnose, and monitor cancer.

Natera will provide funding to the Feinstein Institute, which will contribute blood and tissue samples. Natera will develop technology for detecting ctDNA.

"Our vision is to enable cancer detection across multiple tumor types that will have the same key features as our prenatal tests: early, accurate, and non-invasive," said Natera CEO Matthew Rabinowitz in a statement.

Natera uses a targeted sequencing technology in its Panorama non-invasive prenatal test that analyzes SNPs in cell-free DNA to determine fetal aneuploidy. A similar sequencing strategy could be applied to circulating tumor DNA in cancer patients for monitoring the disease.

"Earlier cancer detection leads to better clinical outcomes," Peter Gregersen, director of the Feinstein Institute's Center for Genomics and Human Genetics, said in a statement. "[W]e are optimistic about the application of Natera's core technology to address the unique challenges in early cancer detection and monitoring."

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.